Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Operating Margin (2016 - 2025)

Historic Operating Margin for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 145.46%.

  • Spero Therapeutics' Operating Margin fell 74200.0% to 145.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 115.46%, marking a year-over-year decrease of 1181000.0%. This contributed to the annual value of 152.91% for FY2024, which is 1773900.0% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Operating Margin is 145.46%, which was down 74200.0% from 17.22% recorded in Q2 2025.
  • Spero Therapeutics' Operating Margin's 5-year high stood at 207.01% during Q4 2022, with a 5-year trough of 1459.98% in Q1 2022.
  • Its 5-year average for Operating Margin is 402.33%, with a median of 250.78% in 2025.
  • The largest annual percentage gain for Spero Therapeutics' Operating Margin in the last 5 years was 12092700bps (2022), contrasted with its biggest fall of -11941900bps (2022).
  • Over the past 5 years, Spero Therapeutics' Operating Margin (Quarter) stood at 1002.26% in 2021, then surged by 121bps to 207.01% in 2022, then crashed by -64bps to 74.07% in 2023, then crashed by -295bps to 144.41% in 2024, then dropped by -1bps to 145.46% in 2025.
  • Its Operating Margin stands at 145.46% for Q3 2025, versus 17.22% for Q2 2025 and 250.78% for Q1 2025.